CollPlant Biotechnologies Ltd. Sponsored ADR

CLGN Healthcare Biotechnology

CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.

3.60 0.08 −2.17%
Market cap
$7.0M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
4/9
Altman Z
−16.87
Beneish M
−3.20
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — 4 2 6 7 2 5 2 4
P/E ratio
8.86 8.86 0.00 0.00 0.00 74.36 0.00 0.00 0.00 0.00
Altman Z-Score
— — (6.01) (8.15) (3.32) 15.34 6.17 4.04 (6.12) (16.87)
P/S ratio
54.76 54.76 3.67 12.26 12.09 10.43 317.34 6.29 80.07 7.21
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 172.59 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(47.33) (20.65) (18.74) (23.55) (23.31) 8.53 0.35 (0.82) (19.67) (41.05)
Beneish M-Score
— 0.22 3.06 2.18 (1.74) (2.16) — 27.27 — (3.20)
P/Operating CF
(5.03) (5.03) 5.75 (17.34) (46.45) (67.39) (28.36) (29.38) (11.90) (5.82)
P/B ratio
9.90 9.90 3.40 6.95 16.57 3.61 2.94 2.43 3.06 2.81
Price to Tangible BV
9.90 9.90 3.63 6.95 16.88 3.63 2.96 2.45 3.09 2.84
EV/Sales
51.64 51.64 2.58 12.98 12.43 8.01 236.33 4.33 67.05 7.00
EV/EBITDA
51.64 51.64 0.00 0.00 0.00 149.45 0.00 0.00 0.00 0.00
EV/Operating CF
0.00 0.00 (10.64) (5.28) (17.14) 50.07 (5.16) (17.17) (2.45) (1.76)
EV/FCF
0.00 0.00 (6.32) (4.20) (15.61) 132.52 (4.71) (12.85) (2.36) (1.75)
Quick Ratio
1.11 3.69 2.70 1.20 1.30 14.60 9.74 8.40 4.29 2.31
Current Ratio
1.19 4.56 3.21 1.46 1.68 14.96 10.20 8.62 4.44 2.53
Net Debt/EBITDA
0.13 0.26 1.40 0.53 0.68 (51.68) 1.85 4.20 0.75 0.56
Debt/Assets
1.98% 45.28% 0.50% 0.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.06 1.40 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.01 0.08 0.60 0.24 0.57 0.50 0.01 0.30 0.02 0.16
Operating CF/Net income
0.69 0.86 0.19 0.51 0.77 10.55 0.81 0.39 0.85 0.82
Capex/Depreciation
(0.57) (0.43) (2.43) (2.71) (0.79) (2.01) (1.22) (0.80) (0.46) (0.03)
Interest Coverage
(62.44) (54.42) (1.95) (2.31) (164.68) 0.30 (53.26) — — —
ROE
(387.61%) (294.98%) (155.43%) (234.83%) (134.83%) 0.96% (43.73%) (23.16%) (79.46%) (117.56%)
ROA
(129.91%) (98.89%) (74.21%) (114.48%) (53.48%) 0.76% (38.04%) (19.53%) (62.87%) (77.90%)
ROIC
(1,044.57%) (326.75%) 0.00% (1,543.49%) (309.13%) 2.25% (410.20%) (329.47%) (824.30%) (5,478.53%)
Return on Tangible Assets
(529.40%) (99.06%) (98.47%) (285.38%) (131.41%) 0.53% (53.70%) (25.47%) (132.87%) (207.46%)
Average Days of Receivables
4,714.22 77.40 37.56 54.95 63.58 16.20 673.85 13.09 413.19 34.48
Research and Development Expense of Revenue
5,731.33% 843.66% 77.32% 190.42% 66.24% 48.79% 3,429.77% 95.67% 2,041.75% 345.30%
Selling, General and Administrative Expense of Revenue
3,772.29% 497.71% 74.25% 157.72% 76.08% 37.98% 2,254.52% 54.71% 1,092.43% 203.80%
Intangible Assets out of Total Assets
0.10 0.05 0.04 0.00 0.01 0.00 0.01 0.01 0.01 0.01
Share Based Compensation of Revenue
1,219.28% 297.92% 28.60% 48.53% 27.28% 10.21% 727.09% 17.67% 333.79% 42.13%
Graham Net Nets
0.04 0.04 0.21 (0.06) (0.01) 0.24 0.28 0.32 0.19 0.12
Graham Number
0.00 45.32 0.00 0.00 0.00 47.33 0.00 0.00 0.00 0.00
Earnings Yield
11.28% 11.28% (21.37%) (39.81%) (7.80%) 1.34% (17.91%) (10.25%) (40.56%) (67.02%)
Free Cash Flow Yield
0.00% 0.00% (11.13%) (25.21%) (6.59%) 0.58% (15.82%) (5.36%) (35.45%) (55.54%)
Revenue per Share
0.41 1.81 11.43 4.65 8.91 15.69 0.27 9.62 0.45 1.94
Operating CF per Share
(27.26) (19.36) (2.78) (11.44) (6.46) 2.51 (12.42) (2.43) (12.30) (7.72)
Capex per Share
(0.69) (0.48) (1.90) (2.93) (0.75) (1.56) (1.19) (0.78) (0.42) (0.02)
Free Cash Flow per Share
(27.95) (19.85) (4.67) (14.37) (7.22) 0.95 (13.61) (3.20) (12.72) (7.74)
Cash per Share
5.35 19.29 12.56 7.63 4.86 43.45 26.90 23.63 10.61 4.88
Shareholders Equity per Share
7.26 9.84 12.36 8.20 6.50 45.26 29.26 24.88 11.76 4.98
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
7.26 9.84 12.36 8.20 6.50 45.26 29.26 24.88 11.76 4.98
Free Cash Flow
(5.63) (5.29) (2.05) (7.16) (4.97) 0.95 (15.01) (3.65) (14.57) (9.45)
Working Capital
0.36 5.05 4.94 1.58 2.29 42.07 28.55 24.77 10.21 4.08
Capital Expenditures
(0.14) (0.13) (0.83) (1.46) (0.52) (1.56) (1.32) (0.89) (0.48) (0.03)
Net Current Asset Value
(0.34) 1.00 3.84 (1.62) (0.69) 38.98 26.17 22.24 7.94 2.04
EV/EBIT
51.64 51.64 0.00 0.00 0.00 1,926.71 0.00 0.00 0.00 0.00
Capex to Sales
1.67 0.27 0.17 0.63 0.08 0.10 4.40 0.08 0.94 0.01
Price to Operating Income
54.76 54.76 0.00 0.00 0.00 2,509.12 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.22 0.29 0.24 0.23 0.31 0.28 0.36 0.40 0.45 0.62
Cash ROIC
(214.81%) (46.28%) (18.67%) (90.51%) (63.54%) 1.07% (24.23%) (6.60%) (56.88%) (78.51%)
Accounts Receivable Turnover
0.10 0.82 16.23 5.36 8.66 17.74 0.48 23.19 1.06 5.88
Accounts Payable Turnover
0.00 0.01 2.26 2.58 3.68 2.19 0.37 1.88 1.76 1.13
Inventory Turnover
0.00 0.09 3.27 2.21 2.79 1.71 0.32 1.86 2.82 1.65
Average Days of Payables
0.00 20,513.00 136.85 161.81 97.03 188.23 1,033.86 179.66 195.42 266.65
Days of Inventory on Hand
0.00 4,915.33 179.09 172.50 153.44 196.79 1,304.88 130.89 98.83 250.47
Average Receivables
0.85 0.59 0.31 0.43 0.71 0.88 0.62 0.47 0.49 0.40
Average Payables
1.16 1.16 0.73 0.73 0.82 0.92 1.08 1.06 0.93 0.74
Average Inventory
0.17 0.17 0.51 0.85 1.08 1.17 1.26 1.07 0.58 0.51
Average Assets
6.08 6.09 8.42 9.75 10.80 31.03 44.50 35.95 26.42 14.75
Average Common Equity
2.04 2.04 4.02 4.75 4.28 24.80 38.70 30.31 20.90 9.77

Fold the line items

Columns are period end dates · fundamentals updated 6 Oct 2026